Atika Capital Management’s United Therapeutics UTHR Stock Holding History

Atika Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,350	Closed	-$7.32M	–	99
2026 Q1	$7.32M	Buy	+12,350	New	+$6.15M	0.92%	32
2025 Q1	–	Sell	-31,000	Closed	-$10.9M	–	100
2024 Q4	$10.9M	Buy	31,000 +3,500	+13%	+$1.29M	1.16%	26
2024 Q3	$9.85M	Sell	27,500 -1,500	-5%	-$507K	1.01%	33
2024 Q2	$9.24M	Buy	+29,000	New	+$7.68M	0.91%	38
2023 Q1	–	Sell	-54,412	Closed	-$15.1M	–	93
2022 Q4	$15.1M	Buy	54,412 +1,412	+3%	+$356K	2.18%	14
2022 Q3	$11.1M	Sell	53,000 -6,000	-10%	-$1.34M	0.94%	48
2022 Q2	$13.9M	Buy	59,000 +10,000	+20%	+$2.03M	1.56%	23
2022 Q1	$8.79M	Buy	+49,000	New	+$9.33M	0.74%	48
2015 Q2	–	Sell	-14,000	Closed	-$2.41M	–	77
2015 Q1	$2.41M	Buy	+14,000	New	+$2.13M	1.61%	28

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Atika Capital Management's UTHR Position: Q2 2026 in Review

Atika Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 12,350 shares — an estimated $7.32M sold.

Atika Capital Management first reported a position in UTHR in Q1 2015 and held it in 9 quarters. The position peaked at $15.1M in Q4 2022. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Atika Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Atika Capital Management sold 12,350 United Therapeutics shares in Q2 2026, an estimated $7.32M.
Atika Capital Management first reported a position in United Therapeutics in Q1 2015 and held it in 9 quarters.
Atika Capital Management's United Therapeutics position peaked at $15.1M in Q4 2022.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.